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Abstract
AIM: To assess the prevalence and stability of 
different antiphospholipid antibodies (APLAs) and their 
association with disease phenotype and progression in 
inflammatory bowel diseases (IBD) patients. 
METHODS: About 458 consecutive patients [Crohn’s 
disease (CD): 271 and ulcerative colitis (UC): 187] were 
enrolled into a follow-up cohort study in a tertiary IBD 
referral center in Hungary. Detailed clinical phenotypes 
were determined at enrollment by reviewing the 
patients’ medical charts. Disease activity, medical 
treatment and data about evolvement of complications 
or surgical interventions were determined prospectively 
during the follow-up. Disease course (development f 
complicated disease phenotype and need for surgery), 
occurrence of thrombotic events, actual state of disease 
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activity according to clinical, laboratory and endoscopic 
scores and accurate treatment regime were recorded 
during the follow-up, (median, 57.4 and 61.6 mo for CD 
and UC). Sera of IBD patients and 103 healthy controls 
(HC) were tested on individual anti-β2-Glycoprotein-I 
(anti-β2-GPI IgA/M/G), anti-cardiolipin (ACA IgA/M/G) 
and anti-phosphatidylserine/prothrombin (anti-PS/PT 
IgA/M/G) antibodies and also anti-Saccharomyces 
cerevisiae antibodies (ASCA IgA/G) by enzyme-linked 
immunosorbent assay (ELISA). In a subgroup of 
CD (n  = 198) and UC patients (n  = 103), obtaining 
consecutive samples over various arbitrary time-
points during the disease course, we evaluated the 
intraindividual stability of the APLA status. Additionally, 
we provide an overview of studies, performed so far, in 
which significance of APLAs in IBD were assessed. 
RESULTS: Patients with CD had significantly higher 
prevalence of both ACA (23.4%) and anti-PS/PT 
(20.4%) antibodies than UC (4.8%, P  < 0.0001 and 
10.2%, P  = 0.004) and HC (2.9%, P  < 0.0001 and 
15.5%, P  = NS). No difference was found for the 
prevalence of anti-β2-GPI between different groups 
(7.2%-9.7%). In CD, no association was found 
between APLA and ASCA status of the patients. 
Occurrence of anti-β2-GPI, ACA and anti-PS/PT was 
not different between the group of patients with active 
vs  inactive disease state according to appropriate 
clinical, laboratory and endoscopic scores in CD as 
well as in UC patients. All subtypes of anti-β2-GPI 
and ACA IgM status were found to be very stable 
over time, in contrast ACA IgG and even more ACA 
IgA status showed significant intraindividual changes. 
Changes in antibody status were more remarkable in 
CD than UC (ACA IgA: 49.9% vs  23.3% and ACA IgG: 
21.2% vs  5.8%). Interestingly, 59.1% and 30.1% of 
CD patients who received anti-TNF therapy showed 
significant negative to positive changes in ACA IgA 
and IgG antibody status respectively. APLA status was 
not associated with the clinical phenotype at diagnosis 
or during follow-up, medical therapy, or thrombotic 
events and it was not associated with the probability of 
developing complicated disease phenotype or surgery 
in a Kaplan-Meier analysis. 
CONCLUSION: The present study demonstrated 
enhanced formation of APLAs in CD patients. However, 
presence of different APLAs were not associated with 
the clinical phenotype or disease course.
Key words: Crohn’s disease; Ulcerative colitis; Disease 
progression; Antiphospholipid antibodies; Anti-β2-
Glycoprotein-I antibodies; Anti-phosphatidylserine/
prothrombin; Anti-cardiolipin antibodies; Thrombosis
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Enhanced serological antibody formation 
is a well-known feature of inflammatory bowel 
diseases. Antiphospholipid antibodies (APLAs) are a 
prothrombotic group of antibodies acquired in various 
inflammatory diseases. However their association 
with clinical phenotype and disease progression is 
still unclear in inflammatory bowel diseases (IBD). In 
the present study we report enhanced formation of 
APLAs in patients with Crohn’s disease, which was not 
associated with clinical phenotype or disease course 
during follow-up in a tertiary referral IBD center from 
Hungary. 
Sipeki N, Davida L, Palyu E, Altorjay I, Harsfalvi J, Antal 
Szalmas P, Szabo Z, Veres G, Shums Z, Norman GL, Lakatos 
PL, Papp M. Prevalence, significance and predictive value 
of antiphospholipid antibodies in Crohn’s disease. World J 
Gastroenterol 2015; 21(22): 6952-6964  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i22/6952.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i22.6952
INTRODUCTION
Enhanced serological antibody formation is a well-known 
feature of inflammatory bowel diseases (IBD). A wide 
range of anti-microbial and autoantibodies have been 
reported to be associated with either Crohn’s disease (CD) 
or ulcerative colitis (UC)[1] as well as with complicated 
disease course. Anti-microbial antibodies are formed 
against different surface carbohydrate (anti-glycans[2]) 
or protein antigens of various gut microbes[3]. The 
first and still most relevant anti-microbial antibody is 
the ASCA (anti-Saccharomyces cerevisiae antibody). 
Autoantibodies are directed against various host 
proteins. Based on recent findings, their existence 
might also be related to enhanced microbial challenge 
to the gut[4,5] due to a disturbed gut innate immune 
system and may trigger an exaggerated adaptive 
immune response. Furthermore, these serological 
antibodies may also be actively involved in the path-
ophysiology of inflammation in IBD[6,7]. 
Antiphospholipid antibodies (APLAs) are a 
prothrombotic group of autoantibodies and established 
as the serological hallmark of antiphospholipid 
syndrome (APS)[8]. These antibodies comprise anti-
cardiolipin (ACA), anti-β2-Glycoprotein-I (anti-β2-GPI), 
and anti- phosphatidylserine/prothrombin antibodies 
(anti-PS/PT). APLAs, however, are also found in a 
variety of disorders (chronic inflammatory diseases[9-12] 
or post infectious conditions[13-16]) not necessarily 
exhibiting prothrombotic activity. Even if non-prothrom-
botic, they may have certain pathogenetic roles in 
several diseases as well[17,18]. 
In IBD, available cross-sectional, mainly single-time 
point studies assessing different aspects of APLAs, 
came to discrepant conclusions regarding formation, 
prevalence, and stability of these antibodies. Their 
clinical significance, including association to thrombotic 
events in IBD is also unclear[19-33] (Table 1). Thus a 
comprehensive evaluation of the primary APLAs in a 
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features of CD and thought to be involved in the 
disease pathogenesis and progression[35]. Theoretically, 
impairment in the function of β2-GPI due to the 
presence of anti-β2-GPI may deteriorate certain 
innate immune functions as well. A novel function 
of the β2-GPI protein with important relevance to 
innate immunity, is its ability to bind and scavenge 
lipopolysaccharide (LPS) through a direct interaction 
between domain 5 (D5) of β2-GPI and LPS[36,37]. 
The aims of this study were to investigate in a large 
IBD cohort: (1) the prevalence and type of APLAs; 
(2) associations between the presence of APLAs and 
clinical phenotype of the disease or its activity; and (3) 
whether the presence of APLAs is associated with the 
disease course or development of thrombosis during 
prospective follow-up. Additionally, we also provide an 
overview of studies, performed over the last 24 years, 
in which significance of APLAs in IBD were assessed. 
MATERIALS AND METHODS
Patient population
We performed a cohort study among adult CD and 
UC patients in a Hungarian tertiary IBD referral center 
(Division of Gastroenterology, Department of Internal 
Medicine, University of Debrecen). In all, 458 well-
characterized, unrelated, consecutive IBD patients 
with a complete clinical follow-up CD: 271 (male/
female: 120/140, age at presentation: 27.7 ± 11.6 
years, disease duration: 6.0 ± 6.7 years) and UC: 187 
(male/female: 86/101, age at presentation: 34.0 ± 
13.2 years, disease duration: 7.4 ± 8.6 years) seen at 
our outpatient clinic were included between January 1, 
2005 and June 1, 2010. Serum samples were obtained 
at enrollment from each patient and frozen at -80C 
until testing. The clinical characteristics of the patients 
at time of inclusion and sample procurement are 
presented in Table 2.
Diagnosis of IBD was based on the Lennard-Jones 
criteria[38]. The disease phenotype (age at onset, 
duration, location, and behaviour) was determined 
according to the Montreal Classification[39]. Clinical 
disease activity was calculated according to the Harvey-
Bradshaw Index (HBI)[40] in CD and the partial Mayo 
score in UC[41]. In this study we followed the European 
Crohn’s and Colitis Organisation guidelines[42] and 
defined HBI ≤ 4 as a state of remission and ≥ 5 as a 
state of active disease. In case of UC, ≤ 3 was defined 
as a state of remission and > 4 as a state of active 
disease. Endoscopic activity was determined according 
to the Simple Endoscopic Score for Crohn’s Disease 
(SES-CD) in CD[43] and the endoscopic component of 
the Mayo score in UC[44]. SES-CD defines endoscopic 
activity as ≥ 3 points and inactive disease ≤ 2 in CD, 
meanwhile in UC a state of active disease was defined 
as ≥ 1 points according to invasive partial Mayo score. 
Detailed clinical phenotypes were determined by 
thorough review of patients’ medical records, which 
large prospectively followed-up IBD cohort is required. 
Current advances may add a new spark to the 
investigation of the role of anti-β2-GPI antibodies in 
the pathomechanism of IBD. The presence of cross-
reactive epitopes on Saccharomyces cerevisiae and 
β2-GPI[34] has been reported in APS and raises the 
possibility that ASCA alone or by cross-reactivity 
with anti-β2-GPI exaggerate the pathologic intestinal 
microvascular processes in IBD and interfering with 
the inhibitory effect of β2-GPI on von Willebrand 
factor-dependent platelet adhesion and aggregation. 
Inflammation and coagulation are closely linked, 
interdependent processes in the microvasculature. 
Coagulation abnormalities at the mucosal level result 
in microthrombi formation, which are well-known 
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Table 2  Clinical characteristics of inflammatory bowel disease 
patients at time of inclusion  n  (%)
CD UC
(n  = 271) (n  = 187)
Male/female (n) 115/156 86/101
Age (yr)1 31 (24.0-41.0) 40 (29.0-52.0)
Age at presentation (yr)1 25 (19.0-33.0) 33 (23.0-43.0)
Duration (yr)1 4 (1.0-9.0) 4 (1.0-11.0)
Familial IBD   12 (4.4) 6 (3.2)
Location
   L1   46 (17.0) Proctitis   30 (16.0)
   L2   67 (24.7) Left-sided 104 (55.6)
   L3 157 (57.9) Extensive   53 (28.3)
   L4 only   1 (0.4)
   All L4 18
Behavior
   B1 154 (56.5) Remitting 174 (93.0)
   B2   56 (20.7) Continuous 12 (6.4)
   B3   61 (22.5) Prolonged 
remission
1 (0.5)
Perianal disease 76 (27.5) -
Arthritis 54 (19.9)   26 (13.9)
Ocular manifestations 65 (24.0) 12 (6.4)
Cutaneous 
manifestation
35 (12.9) 16 (8.6)
PSC 9 (3.3)   8 (4.3)
Steroid use/refractory 242 (89.3)/
32 (13.2)
144 (77.0)/
11 (7.6)
Azathioprine use 196 (72.3)   66 (35.3)
Surgery/multiple in CD 54 (19.6)/
19 (7.0)
  7 (3.7)
Biological use 106 (39.1) 25 (13.4)
Smoking habits
never 219 (80.8) 167 (89.3)
yes   47 (17.3) 18 (9.6)
previous   5 (1.8)   2 (1.1)
Disease activity
Inactive HBI ≤ 4 199 (73.4) Inactive partial 
Mayo ≤ 3
135 (72.2)
Active partial 
Mayo > 4
Active HBI ≥ 5 72 (26.6) 52 (27.8)
1Median (IQR). Location: L1: Ileal; L2: Colonic; L3: Ileocolonic; L4: Upper 
gastrointestinal disease; Behavior: B1: Inflammatory; B2: Stenosing; B3: 
Penetrating; PSC: Primary sclerosing cholangitis; Surgery: CD-related 
abdominal surgery and colectomy in UC; HBI: Harvey-Bradshaw Index; 
CD: Crohn’s disease; UC: Ulcerative colitis.
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had been collected in a uniform format. Medical records 
that documented the presence of extraintestinal 
manifestations [for example, arthritis: peripheral 
and axial; ocular manifestations: conjunctivitis, 
uveitis, iridocyclitis; skin lesions: erythema nodosum, 
pyoderma gangrenosum; arterial (AT) and venous 
thrombosis (VT) or pregnancy loss; and hepatic 
manifestations: primary sclerosing cholangitis (PSC)], 
frequency of flare-ups (frequent flare-up: > 1 clinical 
relapse/year)[45], medication use (e.g., steroid, 
immunosuppressive and/or biological use at any time), 
need for surgery (resection in CD and colectomy in 
UC), the presence of familial IBD, smoking habits, and 
perianal involvement were retrospectively analyzed for 
the period prior to the prospective follow-up.
Phenotypical characterization of IBD patients during 
prospective follow-up
252 of 271 CD patients and 173 of 187 UC patients 
were available to be enrolled into a prospective follow-
up study, where the treating IBD physicians registered 
laboratory data, endoscopic and imaging findings, 
disease activity, medical treatment, date and type 
of complications, surgery and thrombosis during 
regular and extraordinary outpatient follow-up visits 
and inpatient stays. In Hungary, a follow-up visit is 
usually scheduled for every 6 mo at a specialized 
gastroenterology center (the actual interval varies 
between 3-6 mo). Collected data were transferred and 
stored in a database for analysis. In October 1, 2013, 
all patients’ charts and database were reviewed and 
updated for the data points mentioned above. Follow-
up for a particular patient was terminated if there 
was no further record available. Median follow-up was 
57.4 mo (IQR: 40.9-80.1) for CD and 61.6 mo (IQR: 
46.5-81.3) for UC patients. In CD, complicated disease 
behavior was defined as the occurrence of stenosis or 
internal penetration. Perianal fistulazing disease was 
distinguished from internal penetrating disease and 
evaluated separately. Need for surgery was defined 
as CD-related abdominal surgery (resection). Figure 1 
summarizes flow chart of the patients with CD in the 
cohort study. In UC, complicated disease behavior was 
defined as progression of the disease extent or need 
for colectomy.
The control group consisted of 103 age- and 
gender- matched healthy blood donors (male/female: 
46/57, age: 35.3 ±12.6 years old). The control 
subjects did not have any gastrointestinal and/or liver 
disease and were selected from consecutive blood 
donors in Debrecen.
Serological analysis
Anti-β2-GPI, ACA and anti-PS/PT levels in serum 
samples were tested using the semiquantitative 
QUANTA LiteTM
 
aβ2-GPI, ACAIII and aPS/PT IgA, 
IgG and IgM kits (INOVA Diagnostics, San Diego, 
California). These enzyme-linked immunosorbent 
assay (ELISA) kits detect IgA, IgG and IgM antibodies 
against β2-GPI, cardiolipin and the PS/PT complex in 
human serum. Plastic microwell plate wells are coated 
with purified β2-GPI, cardiolipin or PS/PT complex. 
Upon incubation, serum β2-GPI, cardiolipin and PS/PT 
IgA, IgG or IgM antibodies bind to β2-GPI, cardiolipin 
or the PS/PT complex. Unbound protein is removed 
by washing, while bound antibodies are detected 
by human IgA, IgG or IgM horseradish peroxidase-
labelled conjugate. A peroxidase substrate is then 
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Total cohort n  = 271
Follow up from 1st sampling n  = 252
Complication and 
surgery naïve Pts 
n  = 143
Complication and/or 
surgery experienced 
Pts n  = 109
No event
n  = 114
Complication
n  = 29
No event
n  = 66
Event
n  = 43
No surgery
n  = 16
Surgery
n  = 13
Complication only
n  = 5
Complication and surgery
n  = 13
Surgery only
n  = 25
Figure 1  Flow chart of the patients with Crohn’s disease in the cohort study. Event: Complication and/or surgery; Complication: Stricture development and/or 
internal penetration and/or perianal penetration; Surgery: Crohn’s disease-related surgery (resection only). Pts: Patients.
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added. The presence of anti-β2-GPI, ACA and aPS/
PT antibodies is determined spectrophotometrically 
by measuring the signal intensity of each sample 
compared to a five-point calibration curve. All assays 
were performed according to the manufacturer’s 
instructions and were considered positive when titers 
were above the manufacturer’s pre-established cut-
off points (for anti-β2-GPI and ACA assays, ≥ 20 units 
for all the IgA, IgG and IgM, and for anti-PS/PT assays 
≥ 30 units for both the IgG and IgM). In case of anti-
PS/PT IgA the results are presented as OD due to lack 
of established calibrators. Values above the OD cut-off 
0.795 were considered positive for anti-PS/PT IgA. This 
cut-off OD value represented the mean ± SD values of 
the healthy controls. The results were documented in 
absolute OD values and in frequency of positivity. Of 
the 458 IBD samples obtained at enrollment, serologic 
analysis was technically successful in 451 of the 458 
IBD cases. 
ASCA antibody evaluation in CD patients was 
performed in our previous study[46] by ELISA (QUANTA 
LiteTM, INOVA Diagnostics, San Diego, CA) according 
to the manufacturers’ instructions. The results are 
presented as arbitrary units, and values above the cut-
off of 25 units were considered as positive. The results 
were documented in absolute values and in frequency 
of positivity.
All the serological assays were performed in 
a blinded fashion without prior knowledge of the 
patients’ diagnosis or other clinical information. 
Detection of NOD2/CARD15 SNP8, 12, 13 mutations 
NOD2/CARD15 SNP8, SNP12, and SNP13 genotypes 
were performed previously[46] in CD patients (n = 
235), but not in UC patients. NOD2/CARD15 variants 
were detected by denaturing high-performance 
liquid chromatography (dHPLC, Wave DNA Fragment 
Analysis System, Transgenomic Limited, United 
Kingdom). Sequence variation, observed in the dHPLC 
profile, was sequenced on both strands to confirm the 
alteration. Sequencing reactions were performed with 
the ABI BigDye Terminator Cycle Sequencing Kit v1.1 
(Applied Biosystems, Foster City, CA) and samples 
were sequenced on an ABI Prism 310 Genetic Analyzer 
(Applied Biosystems, Foster City, CA). All investigated 
polymorphisms were in Hardy-Weinberg equilibrium 
(data not shown).
Review of the literature
We performed a systematic review of studies reporting 
on APLAs in IBD. Papers were eligible if they presented 
original research in adult IBD patients and reported 
occurrence of APLAs and their possible association with 
disease activity, medication, clinical phenotype of the 
disease, need for surgery and thromboembolic events. 
Case series or case reports were not included. Studies 
had to have been published in peer-reviewed journals. 
We started searching PubMed using the following 
search terms: “antiphospholipid antibodies” OR 
“anticardiolipin antibodies” OR “anti-β2-Glycoprotein-I 
antibodies” OR “phosphatidylserine-dependent anti-
prothrombin antibodies” AND “inflammatory bowel 
disease” OR “Crohn’s disease” OR “ulcerative colitis”. 
Limits were human and time ranging from 1991 until 
2014 (30th of November). This search revealed 15 
articles. In Table 1 we summarize the prevalence and 
clinical significance of APLAs in IBD based on findings 
in relevant literature.
Ethical permission
The study protocol was approved by the regional and 
national committee for research ethics. Each patient 
was informed of the nature of the study and signed an 
informed consent form.
Statistical analysis
Variables were tested for normality using Shapiro 
Wilk’s W test. Continuous variables were summarized 
as mean ± SD or as medians (IQR) according to their 
homogeneity. To evaluate differences between IBD and 
healthy control group, as well as within subgroups of 
patients with IBD the following statistical methods were 
used. Categorical variables were compared with the 
Fisher’s exact test or χ 2-test with Yates correction, as 
appropriate. Continuous variables were compared with 
Student’s t test, one-way analysis of variance (ANOVA), 
or Mann-Whitney’s U test. Kaplan-Meier survival 
curves were plotted for analyzing the association 
between categorical clinical variables or APLAs and 
complicated disease outcomes during follow-up with 
LogRank and Breslow tests. Associations are given as 
OR and HR with a 95%CI. A 2-sided probability value 
< 0.05 was considered to be significant. For statistical 
analysis, GraphPad Prism 6 (San Diego, CA) and SPSS 
15.0 (SPSS Inc, Chicago, IL) programs were used. The 
statistical methods of this study were reviewed by Elek 
Dinya from Semmelweis University, Institute of Health 
Informatics, Development and Further Training.
RESULTS
Frequency of APLA Markers in IBD 
The prevalence rates of anti-β2-GPI, ACA and anti-PS/
PT antibodies are presented in Table 3. ACA positivity 
was associated with increased risk for CD compared 
to the controls (ORACA = 10.18, 95%CI: 3.12-33.24). 
Of the different isotypes, ACA IgA (ORACA IgA = 49.70, 
95%CI: 3.04-813.8, χ 2-test with Yates correction) had 
the highest association to CD. ACA positivity was also 
significantly different between CD and UC. While the 
prevalence of anti-PS/PT was significantly different 
between CD and UC, there was not a significant 
difference between CD and the controls. No difference 
was found for the prevalence of anti-β2-GPI in different 
groups.
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Association between APLA positivity, and other 
serologic markers or NOD2/CARD15 genotypes in CD
In CD, no association was found between APLA and 
ASCA status of the patients. Neither ACA IgA nor IgG 
positivity differed significantly according to presence 
or absence of ASCA IgA and ASCA IgG. Similarly, 
the prevalence of ACA was not associated with the 
presence of major NOD2/CARD15 mutations. NOD2/
CARD15 genotypes were available in 235 CD patients. 
The prevalence of any ACA was not different between 
patients with or without NOD2/CARD15 mutations 
(16.1% and 26.1%, p = NS, χ 2-test with Yates 
correction). 
Association between APLA positivity and actual clinical, 
laboratory or endoscopic activity of the disease
At the time of enrollment, 26.6% of CD patients and 
27.8% of UC patients had active disease according to 
clinical activity scores (Table 1). Occurrence of anti-β2-
GPI, ACA and anti-PS/PT was not different between 
the group of patients with active (2.8%, 29.2% and 
18.1%) and inactive disease state (8.8%, 21.2% and 
21.2%, respectively) signified by HBI ≥ 5. Similarly, 
there was no correlation between the disease activity 
determined by partial Mayo score > 4 and APLA status 
in UC (data not shown). 
Furthermore, the prevalence of any ACA was similar 
between CD patients with C-reactive protein (CRP) 
level > 10 mg/L and those with ≤ 10 mg/L (29.0% 
and 21.1%, p = NS, χ 2-test with Yates correction). 
A total of 87 CD patients had ileocolonoscopy 
at enrollment. The prevalence of any ACA was not 
different according to endoscopic disease activity 
denoted by a SES-CD cut-off value of ≥ 3 (inactive 
vs active: 25.6% and 29.5%). Likewise, ACA IgA and 
ACA IgG level was not associated with CRP level, actual 
HBI or SES-CD score in patients with CD applying 
Spearman correlation analysis (data not shown).
20.3% of the CD patients showed frequent relapse 
during the follow-up. The ACA prevalence was not 
significantly different between patients with or without 
frequent relapse (ACA IgA 23.5% vs 16.7%, ACA IgG 
3.9% vs 10.1% and ACA IgM 2.0% vs 3.5%, p = NS 
for all).
Lastly, we investigated the association between 
disease duration and both the presence and magnitude 
of serologic response in CD. The rate of any ACA 
positivity was the same in all four disease duration 
quartile groups (Q1: 26.9%, Q2: 22.7%, Q3: 22.4% 
and Q4: 23.0%, p = NS, χ 2-test with Yates correction). 
The level of ACA IgA and IgG was also not associated 
with disease duration (Kruskal-Wallis test).
APLA markers and disease progression in CD
A total of 154 (56.5%) CD patients had non-stricturing 
and non-penetrating disease (B1) according to 
Montreal classification at time of sampling. 143 
patients were eligible for a prospective follow-up study. 
The median follow-up was 53.4 mo (IQR: 38.0-79.3). 
Among these complication and surgery naïve patients, 
20.3% (29/143) experienced a complication during 
follow-up (31.03% developed strictures, 44.83% 
internal penetration and 24.14% perianal perforation 
only). The median time to complication was 21.4 mo 
(IQR: 8.1-43.1). In all, 9.1% (13/143) had to undergo 
CD-related abdominal surgery (resection) during the 
follow-up period (Figure 1). Two patients had surgical 
intervention without previous complication due to the 
development of colorectal cancer. In the remaining 
patients the reason for surgery was the occurrence 
of a complication (23.1% stenosis, 46.2% internal 
penetration, 15.4% both). The median time to surgery 
was 50.0 mo (IQR: 30.5-54.5). 
In patients classified as B1, the progression of the 
disease to a first event defined as stenosis, internal 
and/or perianal penetration or CD-related surgery 
(Table 4) was not associated to presence or absence of 
APLA positivity. Furthermore in Kaplan-Meier analysis 
the likelihood for earlier progression to a disease event 
was similar in patients with or without APLA positivity. 
Of the clinical factors, disease location and smoking 
were those that associated with time to development 
of first internal penetrating and/or stricturing com-
plication and frequent relapses to development of 
perianal penetrating disease (Table 5). 
In UC patient group association between APLAs and 
clinical phenotype or progression of the disease was 
not evaluated due to the lack of increased prevalence 
of any APLAs in UC population.
APLA markers and thromboembolic events in IBD 
In total, 5.1% (23/452) of IBD patients had at least 
one thromboembolic event (14 CD and 9 UC patients). 
In CD, 18 events of VT, 1 event of PE and 3 events 
of AT were diagnosed. In UC, 8 events of VT and 1 
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Table 3  Anti-phospholipid antibodies in patients with Crohn’s 
disease, ulcerative colitis, and healthy controls  n  (%)
CD (n  = 265) UC (n  = 186) HC (n  = 103)
Anti-β2-GPI IgG   5 (1.9)   4 (2.2) 2 (1.9)
Anti-β2-GPI IgM   8 (3.0) 12 (6.5) 3 (2.9)
Anti-β2-GPI IgA   7 (2.6)   7 (3.8) 3 (2.9)
Any anti-β2-GPI 19 (7.2) 18 (9.7) 8 (7.8)
ACA IgG     27 (10.2)b,d    4 (2.2)d  2 (1.9)b
ACA IgM 8 (3.0)   4 (2.2) 1 (1.0)
ACA IgA     51 (19.2)b,d    1 (0.5)d  0 (0.0)b
Any ACA     62 (23.4)b,d    9 (4.8)d  3 (2.9)b
Anti-PS/PT IgG 20 (7.5)   9 (4.8) 9 (8.7)
Anti-PS/PT IgM   25 (9.4)b,c    8 (4.3)c  1 (1.0)b
Anti-PS/PT IgA 24 (9.1)c    7 (3.8)c 9 (8.7)
Any anti-PS/PT   54 (20.4)d    19 (10.2)d 16 (15.5)
bP < 0.01, CD vs controls; cP < 0.05, dP < 0.01, CD vs UC. Using χ 2-
test with Yates correction. APLA: Antiphospholipid antibodies; β2-
GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: 
Phosphatidylserine/prothrombin complex; CD: Crohn’s disease; UC: 
Ulcerative colitis.
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events of AT were diagnosed. 7 (1.6%) patients had a 
TE also prior to diagnosis of IBD. 4 (1.5%) CD patients 
had recurrent TE. In women, pregnancy loss occurred 
in 6.4% (10/156) of CD and 6.9% (7/101) of UC 
patients.
CD patients presenting with VT were significantly 
older than those without (median age: 30.0 years vs 
38.5 years, p = 0.003). Of the investigated clinical 
factors and laboratory markers, previous VT event 
(RR = 23.0, 95%CI: 10.6-50.1) and factor V Leiden 
mutation (RR = 8.3, 95%CI: 2.2-31.3) were associated 
with the risk of VT events. At the same time, in 
patients with UC, frequent relapse was associated with 
higher risk of VT event (RR = 6.4, 95%CI: 1.7-24.1). 
However, none of the APLA markers were associated 
with increased risk of VT events in IBD.
Table 6 summarizes the patient characteristics, 
prevalence of APLAs and the known genetic and sero-
logic markers of thrombophilia according to presence 
and type of thrombotic events in CD patients. We 
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Table 4  Antiphospholipid antibodies and clinical characteristics of complication and surgery naïve Crohn’s disease patient cohort  n  (%)
Factor Follow-up of CD B1 at first sampling total cohort (n  = 143)
CD B1 total No complication Perianal change only 
(B1p)
Behaviour change to B2 or 
B3
No surgery Surgery
(n  = 143) (n  = 114) (n  = 7) (n  = 22) (n  = 130) (n  = 13)
Male/female (n) 60/83 45/69 5/2 10/12 55/75 5/8
Age at presentation (yr)1 25 (19.0-34.0) 26 (20.0-34.3) 17 (14.0-31.0) 25 (18.8-34.8) 25 (19.0-34.0) 31 (18.0-35.5)
Duration (yr)1 3 (1.0-6.0) 2 (1.0-7.0) 3 (1.0-5.0) 3 (1.0-5.0) 2 (1.0-6.0) 3 (1.0-10.0)
Location
   L1 30 (21.0) 24 (21.1) 0 (0.0) 6 (27.3) 26 (20.0) 4 (30.8)
   L2 51 (35.7) 44 (38.6)   3 (42.9) 4 (18.2) 48 (36.9) 3 (23.1)
   L3 62 (43.3) 46 (40.4)   4 (57.1) 12 (54.5) 56 (43.1) 6 (46.2)
   L4 only 0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0)
Frequent relapse 27 (18.9) 18 (15.8)2     4 (57.1)2 5 (22.7) 23 (17.7) 4 (30.8)
Smoking habit yes 21 (16.2) 14 (12.3)2 2 (28.6) 8 (36.4)2 21 (16.2) 3 (23.1)
Follow up time from first 
sampling, mo1
53.4 (38.0-79.3) 51.7 (36.9-73.9) 79.8 (42.9-91.4) 64.7 (45.6-85.0) 50.93 (37.25-74.2) 84.03 (60.0-91.7)
Positive markers
Anti-β2-GPI IgG   1.4   1.8 0 0   1.6 0
Anti-β2-GPI IgM   5.0   5.3 16.7 0   5.5 0
Anti-β2-GPI IgA   2.8   1.8 16.7   4.5   3.1 0
Any anti-β2-GPI   8.5   8.8 16.7   4.5   9.4 0
ACA IgG   9.2 11.5 0 0 10.2 0
ACA IgM   2.8   3.5 0 0   3.1 0
ACA IgA 17.0 18.6 33.3   4.5 18.8 0
Any ACA 19.9 22.1 33.3   4.5 21.9 0
Anti-PS/PT IgG   8.5   8.0 0 13.6   7.8 15.4
Anti-PS/PT IgM   7.8   8.8 16.7 0   7.8   7.7
Anti-PS/PT IgA   9.9   9.7 16.7   9.1 10.9 0
Any anti-PS/PT 20.6 19.5 33.3 22.7 20.3 23.1
1Median (IQR); 2Using  χ 2-test with Yates correction (P ≤ 0.01); 3Using Mann-Whitney test (P < 0.01). Location: L1: Ileal; L2: Colonic; L3: Ileocolonic; 
L4: Upper gastrointestinal disease; Behavior: B1: Inflammatory; B2: Stenosing; B3: Penetrating. APLA: Antiphospholipid antibodies; β2-GPI: Beta2-
glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex; CD: Crohn’s disease.
Table 5  Univariate Kaplan Meier and Log-rank analysis of serologic and clinical factor associated with complicated disease course in 
B1 Crohn’s disease patients (n  = 143)
Variable Internal penetrating and/or stricturing 
complication
Perianal penetrating complication CD-related abdominal surgery
HR (95%CI) P LogRank-value HR (95%CI) P LogRank-value HR (95%CI) P LogRank-value
Gender - male 1.10 (0.47-2.55) 0.83 2.69 (0.80-9.03) 0.11 0.91 (0.33-2.55) 0.86
Smoking    3.72 (1.23-11.21)1  0.021 1.61 (0.36-7.19) 0.53 1.64 (0.45-5.97) 0.45
Location (colon only)  0.41 (0.17-0.96)1  0.041 1.00 (0.29-3.43) 0.99 0.61 (0.22-1.74) 0.36
Frequent relapse 1.10 (0.39-3.07) 0.85   7.29 (1.72-30.99)1    0.0071 1.64 (0.44-6.10) 0.46
APLA at all 1.36 (0.59-3.16) 0.47 1.30 (0.40-4.27) 0.66 1.37 (0.49-3.80) 0.55
Anti-β2-GPI at all 0.56 (0.13-2.32) 0.42 0.99 (0.13-7.70) 0.99 0.33 (0.06-1.81) 0.20
ACA at all 0.41 (0.13-1.26) 0.12 1.12 (0.23-5.49) 0.89 0.30 (0.07-1.27) 0.10
Anti-PS/PT at all 1.07 (0.39-2.97) 0.89 1.74 (0.38-8.03) 0.48 1.11 (0.29-4.18) 0.88
1The PLogRank-value < 0.05. APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/
prothrombin complex.
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further investigated the probability for thromboembolic 
events as a function of positivity for a certain amount 
of APLAs out of the whole panel. However, neither 
CD and nor UC patients positive for multiple APLAs 
showed a higher probability for the development of 
thromboembolic events.
Stability of APLA markers 
In order to evaluate the stability in the APLA status 
(positive or negative for a respective antibody), we 
analyzed samples from same patients over various 
arbitrary time-points during the disease course. At 
least two serum samples were taken from a subgroup 
of CD patients (n = 198) and UC patients (n = 103). 
Median time between sample procurements were 13.5 
mo (IQR: 6.8-22.9 mo) for CD and 12.1 mo (IQR: 
5.7-20.4 mo) for UC patients. Interestingly, the anti-
β2-GPI status was very stable over time with respect to 
all three Ig subtypes. Only 1.5%-5.8% of either CD or 
UC patients had a change in their anti-β2-GPI antibody 
status compared to the initial sample procurement. At 
the same time marked differences were found in case 
of ACA Ig subtypes. ACA IgM status, similar to anti-β2-
GPI, was also stable. In contrast, ACA IgG and even 
more ACA IgA status showed significant changes over 
time, mainly from negative to positive. Changes in 
antibody status were more remarkable in CD than UC 
(ACA IgA: 49.9% vs 23.3% and ACA IgG: 21.2% vs 
5.8%). Stability data are not available for anti-PS/PT 
antibodies since measurements were only preformed 
on the first available serum samples of the patients. 
APLA changes are summarized in Table 7. 
After availability of tumor necrosis factor (TNF) 
antagonist therapy through National Health reimbur-
sement system in 2008, 43.7% (110/252) of our 
patients received either infliximab or adalimumab 
treatment. We assessed the impact of post-enrolment 
anti-TNF therapy in the induction of new ACA antibody 
formation. 59.1% (55/93) of patients who received 
anti-TNF therapy and had negative findings for ACA 
IgA at the baseline were found to have positive results 
later on (negative to positive change), which was 
significantly higher compared to the proportion of 
35.6% (36/101) found among patients who did not 
receive anti-TNF therapy at all (p = 0.004). These 
ratios were 30.1% vs 12.9% (p = 0.033) for ACA IgG.
DISCUSSION
To our knowledge, this is the largest study to 
investigate prospectively the prevalence, type, and 
clinical significance of multiple APLAs simultaneously 
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Table 6  Antiphospholipid antibodies, thrombophilia markers and clinical characteristics of total Crohn’s disease according to 
presence and type of thrombosis  n  (%)
Factor Follow-up of CD Total Cohort from diagnosis (n  = 265)
No thrombosis Arterial thrombosis Venous thrombosis No pregnancy loss Pregnancy loss
(n  = 251) (n  = 3) (n  = 11) (n  = 146) (n  = 10)
Male/female 104/147 1/2 7/4 146/0 10/0
Age at presentation (yr)1 25.0 (19.0-33.0) 40.0 (28.0-42.0) 29.5 (23.3-39.3) 26.0 (20.0-35.0) 25.5 (21.0-35.0)
Frequent relapse 48 (20.2) 0 (0.0) 4 (36.4) 33 (24.1)   2 (20.0)
Previous thrombosis  1 (0.4)3 0 (0.0)  4 (36.4)3 2 (1.4) 0 (0.0)
Smoking habits yes 48 (19.1) 0 (0.0) 3 (27.3) 22 (15.1)   2 (20.0)
Follow up time from diagnosis, mo1 102.2 (63.3-172.8)2 149.9 (130.8-219.8) 186.3 (142.0-244.2)2 109.0 (61.8-184.6) 136.5 (95.4-180.6)
Positive markers (%)
   Anti-β2-GPI IgG and/or IgM   4.8 0   9.1   4.9 10
   Anti-β2-GPI IgA   2.8 0 0   4.9   0
   ACA IgG and/or IgM 12.1 0 27.3 13.9 10
   ACA IgA 19.0 66.7 0 20.1 10
   Anti-PS/PT IgG and/or IgM 14.6 50.0 36.4 18.3 40
   Anti-PS/PT IgA   8.9 50.0   9.1   7.7 10
   At least 1 APLA pos 48.0 66.7 54.5 52.8 60
   At least 2 APLA pos 16.1 33.3   9.1 18.1 10
   At least 3 APLA pos   3.2 0   9.1   4.9   0
Thrombophilia markers3 (%)
   LA   7.5 0 0   5.1   0
   PS deficiency 
   (inherited and/or acquired)
  8.1 0 25.0 12.7   0
   ATIII deficiency 
   (inherited and/or acquired)
0 0 0 0   0
   PC deficiency 
   (inherited and/or acquired)
  3.0 0 0   4.8   0
   FV Leiden    5.94 0  42.94   7.8   0
   FII20210A   5.9 0 16.7   7.8   0
1Median (IQR); 2Using Kruskal-Wallis test (P ≤ 0.01); 3Using χ 2-test with Yates correction (P ≤ 0.05); 4Serologic and genetic markers of thrombophilia 
were available in 105 patients. pts: Patients; APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: 
Phosphatidylserine/prothrombin complex.
Sipeki N et al . Papp M APLA in IBD
in a cohort of IBD patients to date. Three different 
antibodies were assessed by ELISA. Contrary to 
routine laboratory practice, APLAs were identified by 
anti-IgA secondary antibody in addition to anti-IgG 
and anti-IgM isotypes. Moreover, in the present study 
we also provided an overview of relevant APLA studies 
in IBD.
We demonstrated, for the first time, that enhanced 
ACA IgA formation is a feature of CD; the presence 
of ACA IgA was significantly higher as compared to 
UC and HC. Previously only one study[22], involving 
50 CD patients, evaluated the occurrence of ACA IgA. 
However, the reported prevalence rate was much 
lower than in the present study (6.0% vs 19.2%). 
At the same time, occurrence of IgM and IgG class 
ACA was studied more extensively in IBD, but several 
studies provide only total prevalence rate for these 
two ACA subtypes. Reported prevalence of total ACA 
was widely varied both in CD (0.0%-36%)[21,22,25] and 
UC (1.3%-20.0%)[30,31] which was 12.6% and 4.3%, 
respectively in the present study. Studies evaluating 
separately these two subtypes of ACA revealed that 
the increased ACA prevalence is mainly due to IgG 
subtype. Except one study[30], occurrence of ACA IgG 
prevailed over ACA IgM[20,22,25]. This is concordant with 
our results in CD cohort (ACA IgG: 10.2 vs ACA IgM: 
3.0%). 
What can be the cause of enhanced ACA formation 
in CD? Animal models, immunization with lipid A 
and lipoteichoic acid have resulted in induction of 
ACA and/or lupus anticoagulant (LA) formation[47]. 
Moreover, appearance of ACA antibodies may be due 
to the sustained exposure to bacterial DNA, which is 
enriched in unmethylated CpG motifs. These motifs 
are expressed e.g. in Escherichia coli DNA[48]. Based 
on these literature findings, the role of bacterial 
translocation (BT) in the induction of ACA, similar to 
anti-microbial antibodies, seems plausible[1]. At the 
same time, we did not find any association between 
the presence of ACA and ASCA, even when assessing 
according to separate isotypes. This finding implies 
mechanisms other than BT in the formation of ACA. 
Moreover, in contrast to anti-microbial antibodies, 
APLA formation was not influenced by NOD2/CARD15 
genotypes. The fact that neither the presence of ACA, 
nor the titers of the antibodies were affected by actual 
disease activity and were also not associated with 
the CD phenotype of frequent relapse contradict the 
involvement of BT in the formation mechanisms of 
ACA as well.
Former studies[19-26] extensively assessed the link 
between disease activity and APLA formation either 
by clinical activity or by CRP level, but found no 
association. Considering that clinical, laboratory and 
endoscopic activity are not inevitably congruent in 
all cases, in the present study, we re-evaluated this 
relationship in a complex way, applying all the three 
kinds of activity parameters simultaneously, but came 
to same conclusion.
The prevalence of anti-β2-GPI IgG/IgM in the 
present study was comparable to those reported in the 
study of Koutroubakis et al[25] (CD: 5.0% vs 4.4% and 
UC: 7.5% vs 10.8%). Anti-PS/PT antibodies were not 
assessed previously in IBD, however we did not find 
enhanced antibody formation in IBD as compared to 
HC. 
Association of certain APLAs with clinical phenotype 
of IBD was mainly assessed in the cross-sectional 
single-time point studies summarized in Table 1. In 
most of these studies, these antibodies were neither 
linked to the disease location[19,21,22,25], behavior[25] and 
need for surgery[19] in CD patients, nor to the extent of 
the disease[19,21,24,25] and colectomy[19] in UC patients. 
Likewise, different APLAs were not associated with 
the risk of VTE events in either CD[19,22,23,25,26] or in 
UC[19,23-25]. In case of these single point cross sectional 
studies the serum samples were obtained at different 
times during the disease course. These approaches 
combine samples taken before, at the time of and 
after complications occur and only allow revealing 
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Table 7  Stability of antiphospholipid antibodies marker status 
over time in inflammatory bowel diseases patients with at 
least 2 samples during the disease course  n  (%)
APLA marker CD (n  = 198) UC (n  = 103)
Anti-β2-GPI IgG
   Stable negative 194 (98.0) 97 (94.2)
   Stable positive   1 (0.5) 2 (1.9)
   Neg. to pos.   0 (0.0) 3 (2.9)
   Pos. to neg.   3 (1.5) 1 (1.0)
Anti-β2-GPI IgM
   Stable negative 186 (94.0) 94 (91.3)
   Stable positive   4 (2.0) 3 (2.9)
   Neg. to pos.   6 (3.0) 5 (4.9)
   Pos. to neg.   2 (1.0) 1 (0.9)
Anti-β2-GPI IgA
   Stable negative 190 (96.0) 93 (90.3)
   Stable positive   1 (0.5) 4 (3.9)
   Neg. to pos.   3 (1.5) 5 (4.9)
   Pos. to neg.   4 (2.0) 1 (0.9)
ACA IgG
   Stable negative 139 (70.2) 95 (92.2)
   Stable positive   3 (1.5) 1 (1.0)
   Neg. to pos.   42 (21.2) 6 (5.8)
   Pos. to neg. 14 (7.1) 1 (1.0)
ACA IgM
   Stable negative 173 (87.4) 95 (92.2)
   Stable positive   3 (1.5) 1 (1.0)
   Neg. to pos. 18 (9.1) 7 (6.8)
   Pos. to neg.   4 (2.0) 0 (0.0)
ACA IgA
   Stable negative   73 (36.9) 78 (75.7)
   Stable positive 13 (6.6) 0 (0.0)
   Neg. to pos.   93 (46.9) 24 (23.3)
   Pos. to neg. 19 (9.6) 1 (1.0)
Anti-PS/PT measurements were only preformed on the first available 
serum samples of the patients. APLA: Antiphospholipid antibodies; 
β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: 
Phosphatidylserine/prothrombin complex; CD: Crohn’s disease; UC: 
Ulcerative colitis.
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associations, but do not have predictive capability. 
In the present study to enhance the potential clinical 
value of these markers, we applied a prospective 
study design, which enabled us to evaluate the 
potential predictive capabilities of APLAs in respect 
to complicated CD behavior and surgery. Predictive 
ability for serum markers might be beneficial at any 
time during the disease course but perform distinctly 
by chance. Thus we formed two separate groups for 
our CD cohort (1) complication and surgery naïve 
CD patients; and (2) complication and/or surgery 
experienced patients prior to sample procurement. 
Several observations suggest that the presence of 
perianal and internal penetrating disease signify 
distinct phenotypes in CD concerning all the clinical, 
serologic and genetic point of view[1,49]. Accordingly, 
we evaluated B1p complication separately from B3 
complication. However, APLA did not proved as a 
predictive marker of the complicated disease in neither 
clinically setting of CD. A clear strength of our study 
was prospective follow-up design and the application 
of the widest panel of currently available APLAs.
Due to low frequency of different thromboembolic 
complications, we assessed the occurrence of these 
events even from the diagnosis involving the period 
prior to sample procurement as well. Development 
of VT, AT and pregnancy loss, however, did not vary 
according to APLA status. 
At the same time, significant changes were found 
in ACA IgA and ACA IgG positivity over time in patients 
with CD. In rheumatology disorders, introduction 
of TNF antagonists (adalimumab, infliximab, and 
etanercept) was reported to induce production of 
various types of autoantibodies, such as APLAs[50]. 
However such data are scarce in IBD. In a study by 
Atzeni et al[20] involving 63 patients with CD, 5 (8%) 
had ACA antibodies (mainly IgM) at baseline and two 
additional patients developed these autoantibodies 
during infliximab treatment with no apparent clinical 
effect. Thus we investigated the possible role of the 
TNF antagonists therapy in our prospective CD cohort. 
Interestingly, the patients initially negative for ACA 
developed ACA IgA or IgG positivity significantly more 
frequently if they received anti-TNF therapy suggesting 
a causative association. In the non-anti-TNF treated 
subgroup of patients, the change of the ACA status is 
less well understood and needs further clarification. 
The pathogenic mechanism that changes the humoral 
response leading to development of autoimmunity 
during anti-TNF inhibitors therapy is unknown, but 
various hypothesis have been proposed[51]. One 
hypothesis is that binding of anti-TNF antagonists to 
the transmembrane and soluble TNF, rapidly lowering 
TNF level and enhancing apoptotic cell death, which 
triggers the development of autoantibodies. Further 
investigations are warranted to elucidate whether 
the new ACA appears associated with a worse clinical 
outcome.
In conclusion, the present study demonstrated 
enhanced formation of APLAs in CD patients. The 
presence of the APLAs however was not associated 
with the clinical phenotype, disease course, or risk 
of venous thrombotic events during the prospective 
follow-up.
COMMENTS
Background
Enhanced serological antibody formation is a well-known feature of inflammatory 
bowel diseases (IBD). A wide range of anti-microbial and autoantibodies have 
been reported to be associated with either Crohn’s disease (CD) or ulcerative 
colitis (UC) as well as with complicated disease course. Autoantibodies are 
directed against various host proteins. Based on recent findings, their existence 
might also be related to enhanced microbial challenge to the gut due to a 
disturbed gut innate immune system and may trigger an exaggerated adaptive 
immune response. Furthermore, these serological antibodies may also be 
actively involved in the pathophysiology of inflammation in IBD. Antiphospholipid 
antibodies (APLAs) are a prothrombotic group of antibodies acquired in various 
inflammatory diseases. These antibodies comprise anti-cardiolipin (ACA), anti-
β2-Glycoprotein-I (anti-β2-GPI), and anti-phosphatidylserine/prothrombin 
antibodies (anti-PS/PT). Their association with clinical phenotype and disease 
progression is still unclear in IBD. Even if non-prothrombotic, they may have 
certain pathogenetic roles in several diseases as well. 
Research frontiers
In IBD, available cross-sectional, mainly single-time point studies assessing 
different aspects of APLAs, came to discrepant conclusions regarding 
formation, prevalence, and stability of these antibodies. Their clinical 
significance, including association to thrombotic events in IBD is also unclear. 
Thus a comprehensive evaluation of the primary APLAs in a large prospectively 
followed-up IBD cohort is required. Current advances may add a new spark to 
the investigation of the role of anti-β2-GPI antibodies in the pathomechanism of 
IBD.
Innovations and breakthroughs
This is the largest study to investigate prospectively the prevalence, type, and 
clinical significance of multiple APLAs simultaneously in a cohort of IBD patients 
to date. Three different antibodies were assessed by ELISA. Contrary to routine 
laboratory practice, APLAs were identified by anti-IgA secondary antibody in 
addition to anti-IgG and anti-IgM isotypes. Moreover, in the present study the 
authors also provided an overview of relevant APLA studies in IBD. Although 
they detected enhanced formation of APLAs in CD patients, the presence of the 
APLAs was not associated with the clinical phenotype, disease course, or risk 
of venous thrombotic events during the prospective follow-up. A clear strength 
of this study was prospective follow-up design and the application of the widest 
panel of currently available APLAs.
Applications
Previous studies investigating APLAs in IBD patients had certain shortcomings 
resulting in an inconclusive, contradictory and confusing viewpoint regarding 
their pathogenetic and clinical significance, as well as their predictive value. 
Based on these large scale and extensive evaluation of APLAs they were not 
proved as a predictive marker of the complicated disease course in neither 
clinically settings of CD. Thromboembolic events were also not associated to 
any individual or multiple APLA positivity. Therefore use of APLAs in everyday 
practice and decision making cannot be recommended.
Terminology
APLAs are a prothrombotic group of antibodies acquired in various inflammatory 
diseases. These ACA, anti-β2-GPI, and anti-PS/PT. Bacterial translocation is 
defined as an enhanced passage of bacteria and/or bacterial products from the 
intestinal tract to systemic circulation. 
Peer-review
This article relooks at the role of APLAs in IBD and provides a small systematic 
review of the currently available literature. The authors show the analysis of 
APLAs in patients with IBD (n = 458) using prospective cohort study. The 
manuscript has extensive information on APLAs. This is a well-designed and 
conducted study and gives clear conclusion that despite increased occurrence 
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of APLAs in IBD, they are not associated with disease phenotype including the 
thrombosis and do not need further study unless a newer aspect comes in future. 
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